LICENSE AGREEMENTS (Details) $ in Millions			12 Months Ended
	Apr. 11, 2022 USD ($) shares	Aug. 06, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2016 USD ($)	Jul. 19, 2021 USD ($)	May 06, 2020 licenseAgreement
Assets Sold under Agreements to Repurchase [Line Items]
Milestone payment		$ 0.5
Number of amended and restated license agreements | licenseAgreement							2
Accrued milestone fees			$ 0.5	$ 0.6
European Biomedical Research Institute Of Salerno, Italy
Assets Sold under Agreements to Repurchase [Line Items]
License fees	$ 1.0
Milestone payment	0.5
European Biomedical Research Institute Of Salerno, Italy | Common Stock | License Agreement
Assets Sold under Agreements to Repurchase [Line Items]
Consideration received on transaction	$ 0.5
European Biomedical Research Institute Of Salerno, Italy | Common Stock, Unregistered | License Agreement
Assets Sold under Agreements to Repurchase [Line Items]
Number of shares issued on transaction (in shares) | shares	43,708
Lobesity Acquisition
Assets Sold under Agreements to Repurchase [Line Items]
Regulatory and clinical milestone payments						$ 45.5
Maximum | Lobesity Acquisition
Assets Sold under Agreements to Repurchase [Line Items]
Regulatory and clinical milestone payments						58.0
Sales related milestone payments						50.0
Alba Agreement
Assets Sold under Agreements to Repurchase [Line Items]
License fees					$ 0.5
Milestone payment					1.5
Sales range, minimum					100.0
Sales range, maximum					1,500.0
Milestone sales target value					1,500.0
Alba Agreement | License and Service
Assets Sold under Agreements to Repurchase [Line Items]
License and service revenue					150.0
Payment for sale of product					$ 2.5
Cedars License
Assets Sold under Agreements to Repurchase [Line Items]
Milestone payment			9.4
Lobesity License | Lobesity Acquisition
Assets Sold under Agreements to Repurchase [Line Items]
Regulatory and clinical milestone payments						45.5
Lobesity License | Maximum | Lobesity Acquisition
Assets Sold under Agreements to Repurchase [Line Items]
Regulatory and clinical milestone payments						58.0
Sales related milestone payments						$ 50.0
U.S and EU | Amunix License, GLP-1
Assets Sold under Agreements to Repurchase [Line Items]
Milestone payment			70.4
U.S and EU | Amunix License, GLP-2
Assets Sold under Agreements to Repurchase [Line Items]
Milestone payment			60.1
China and Related Territories | Amunix License, GLP-1
Assets Sold under Agreements to Repurchase [Line Items]
Milestone payment			20.5
South Korea And Eastern Asia | Amunix License, GLP-1
Assets Sold under Agreements to Repurchase [Line Items]
Milestone payment			$ 20.5